NewLimit raised a $435 million Series C to bring its aging reprogramming medicine into human trials.
- Amount
- $435M
- Stage
- Series C
- Announced
- 7 June 2026
- Lead
- Founders Fund
- Other investors
- Thrive Capital, Greenoa
- Checked
- Amount and date checked against the press source